AZD 4635

Drug Profile

AZD 4635

Alternative Names: AZD-4635; HTL 1071

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Heptares Therapeutics
  • Developer AstraZeneca; Heptares Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Chemokine receptor antagonists; G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 05 Apr 2017 Heptares Therapeutics completes a preclinical study in Cancer
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Apr 2017 Interim pharmacodynamics data from a preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top